0913693 B.c.(OTC) REPCF

Current Price$0.00

Market Cap$7.00K

Since IPO (2010)-100%

5 Year-100%

1 Year-95%

1 Month+0%

0913693 B.c. last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-06-23

0913693 B.c. stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-04-06
1 month	+0%	USD 0.00	2026-04-06
3 month	+0%	USD 0.00	2026-03-18
Year to date	+0%	USD 0.00	2025-11-06
1 year	-95%	USD 0.00	2025-05-19
3 year	-99.91%	USD 0.12	2023-06-23
5 year	-99.97%	USD 0.33	2021-06-24
Since inception	-100%	USD 15.50	2010-12-23

0913693 B.c. Financials at a Glance

Market Cap

$7.00K

Revenue (TTM)

CA$442.11K

Net Income (TTM)

CA$7.77M

EPS (TTM)

-$0.08

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-146.64 (Low)

Dividend

$0.00

Beta (Volatility)

-146.64 (Low)

Price

$0.00

Volume

1,455

Open

$0.00

Price

$0.00

Volume

1,455

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 4, 2025

Dividend

$0.00

Beta (Volatility)

-146.64 (Low)

Price

$0.00

Volume

1,455

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 4, 2025

REPCF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About 0913693 B.c.

RepliCel Life Sciences Inc. is a biotechnology firm based in Vancouver, Canada, specializing in regenerative medicine. The company focuses on developing patient-specific cell therapies to address functional cellular deficits.

Products and Services

RCT-01 targets chronic tendinosis
RCS-01 treats aging and sun-damaged skin
RCH-01 aims to alleviate hair loss

Growth Outlook

Partnerships with YOFOTO and Shiseido enhance research capabilities
Innovative RCI-02 device for dermal injections is in development
Collaboration with the University of British Columbia strengthens research initiatives

Financial Highlights

Recent quarterly revenue of 88,661 CAD shows potential growth
Trailing twelve months (TTM) revenue of 353,445 CAD indicates upward trend
Net income for Q4 2025 was 7,872,155 CAD, showcasing profitability

RepliCel Life Sciences Inc. is positioned in the biotechnology sector, focusing on innovative therapies that leverage the body's own cells. The company's product pipeline includes several promising candidates aimed at addressing common health issues, such as chronic tendinosis and hair loss. Recent partnerships and collaborations are expected to enhance research and development efforts, potentially leading to significant advancements in treatment options. Financially, the company has shown a notable increase in revenue and profitability in recent quarters, indicating a positive trajectory for future growth.

AI Generated • Jun 27, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

CEO

Andrew Schutte

Website

www.replicel.com

Headquarters

Vancouver, BC V6C 3P1, CA

REPCF Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-101.77%

Net Income Margin

-27.50%

Return on Equity

1.86%

Return on Capital

N/A

Return on Assets

-33.81%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.00K

Shares Outstanding

70.00M

Volume

1.46K

Avg. Volume

23.468

Financials (TTM)

Gross Profit

CA$88.43K

Operating Income

CA$460.22K

EBITDA

CA$460.36K

Operating Cash Flow

-CA$179.10K

Capital Expenditure

CA$8.30

Free Cash Flow

-CA$179.10K

Cash & ST Invst.

CA$815.10

Total Debt

CA$1.07M

0913693 B.c. Performance Analysis

0913693 B.c. annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	CAD 271,716	-3.7%
2023	2023-12-31	CAD 262,087	-3.5%
2024	2024-12-31	CAD 258,209	-1.5%
2025	2025-12-31	CAD 253,158	-2.0%

0913693 B.c. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-100.0%
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	-74.9%

0913693 B.c. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	CAD -0.02	-84.9%
2023	2023-12-31	CAD -0.00	-74.2%
2024	2024-12-31	CAD -0.00	-71.8%
2025	2025-12-31	CAD -0.00	272.7%

0913693 B.c. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	99.7%
Q3	2025-09-30	175.0%
Q4	2025-12-31	36566.7%
Q1	2026-03-31	-100.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

CA$88.66K

+44.3%

Gross Profit

CA$88.43K

N/A

Gross Margin

99.74%

N/A

Market Cap

$7.00K

N/A

Market Cap/Employee

$7.00K

N/A

Employees

N/A

Net Income

-CA$47.58K

+99.4%

EBITDA

CA$78.39K

+154.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

CA$815.10

-92.2%

Total Debt

CA$1.07M

+24.2%

Accounts Receivable

CA$38.08K

+774.5%

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

-100.0%

Short Term Debt

CA$1.07M

+34.0%

Return on Assets

-33.81%

N/A

Return on Invested Capital

23.46%

N/A

Free Cash Flow

-CA$34.35K

+77.3%

Operating Cash Flow

-CA$34.35K

+77.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

RGBPRegen BioPharma, Inc.

RGBPRegen BioPharma, Inc.$0.00+7.14%

HAVLFHAVN Life Sciences Inc.

HAVLFHAVN Life Sciences Inc.$0.00+0.00%

SIGYSigyn Therapeutics, Inc.

SIGYSigyn Therapeutics, Inc.$0.03+0.00%

AXIMAXIM Biotechnologies, Inc.

AXIMAXIM Biotechnologies, Inc.$0.00-10.31%

TBRIFTherma Bright Inc.

TBRIFTherma Bright Inc.$0.04+0.00%

PKTXProtoKinetix, Incorporated

PKTXProtoKinetix, Incorporated$0.01+0.00%

ZLDAFZelira Therapeutics Limited

ZLDAFZelira Therapeutics Limited$0.30+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

FFord Motor Company

FFord Motor Company$14.37+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$11.93+0.09%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.00-0.03%

Questions About REPCF

What is the current price of 0913693 B.c.?

0913693 B.c. is trading at $0.00 per share.

What is the 52-week range for 0913693 B.c.?

Over the past 52 weeks, 0913693 B.c. has traded between $0.00 and $0.00.

How much debt does 0913693 B.c. have?

As of the most recent reporting period, 0913693 B.c. reported total debt of CA$761.60K.

How much cash does 0913693 B.c. have on hand?

0913693 B.c. reported CA$582.57 in cash and cash equivalents in its most recent financial results.

What is 0913693 B.c.’s dividend yield?

0913693 B.c. does not currently have a dividend yield.

0913693 B.c.(OTC) REPCF

0913693 B.c. Financials at a Glance

REPCF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About 0913693 B.c.

REPCF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

0913693 B.c. Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About REPCF

What is the current price of 0913693 B.c.?

What is the 52-week range for 0913693 B.c.?

How much debt does 0913693 B.c. have?

How much cash does 0913693 B.c. have on hand?

What is 0913693 B.c.’s dividend yield?

Premium Investing Services